Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Key Highlights
- ➤Telomir (TELO) raises approximately $5.6 million through a common-stock PIPE financing
- ➤John Paul DeJoria invests an additional $1.0 million in Telomir
- ➤Telomir issues 4,843,300 shares at $1.16 each, a 5% VWAP discount
- ➤FDA clears Telomir-Zn’s IND for a first-in-human Phase 1/2 TNBC trial
- ➤Net proceeds will primarily fund Telomir-Zn clinical development and corporate purposes
Expert Statements
John Paul DeJoria, Existing significant shareholder of Telomir; co-founder of John Paul Mitchell Systems and Patrón Spirits
“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir”
John Paul DeJoria, Existing significant shareholder of Telomir; co-founder of John Paul Mitchell Systems and Patrón Spirits
“Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease.”
John Paul DeJoria, Existing significant shareholder of Telomir; co-founder of John Paul Mitchell Systems and Patrón Spirits
“Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”
Erez Aminov, Chairman and CEO of Telomir
“We have been very deliberate about how and when we access the capital markets”
Erez Aminov, Chairman and CEO of Telomir
“Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders.”
Erez Aminov, Chairman and CEO of Telomir
“As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”
MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, without any accompanying investor warrants or convertible securities.
The financing includes an additional $1.0 million investment from billionaire entrepreneur and existing significant shareholder John Paul DeJoria, co-founder of John Paul Mitchell Systems and Patrón Spirits. Other existing shareholders and new investors also participated in the financing.
Get started
Create a free account to read the full story.